Use 60 mg Edoxaban for This Patient
For a patient weighing approximately 60 kg on phenytoin, you should use the standard 60 mg once-daily dose of edoxaban, not the reduced 30 mg dose. Your clinical reasoning is correct: phenytoin is a potent P-glycoprotein inducer that will significantly decrease edoxaban levels, and this drug interaction overrides the body weight consideration.
Why 60 mg is the Correct Choice
Dose Reduction Criteria Are Not Met
According to the 2024 ESC Guidelines 1 and 2023 ACC/AHA Guidelines 2, edoxaban dose reduction from 60 mg to 30 mg is indicated only if ANY of the following apply:
- Creatinine clearance 15-50 mL/min
- Body weight ≤60 kg (not "approximately 60 kg")
- Concomitant use of P-glycoprotein inhibitors (ciclosporin, dronedarone, erythromycin, or ketoconazole)
Critical distinction: Your patient weighs approximately 60 kg, which means they are likely at or slightly above this threshold. The dose reduction criterion specifies body weight ≤60 kg, not "around 60 kg." This is a hard cutoff, and borderline cases should not trigger dose reduction.
Phenytoin Creates a Compelling Contraindication to Dose Reduction
Phenytoin is a potent P-glycoprotein inducer (opposite of the inhibitors listed above). This means it will:
- Increase edoxaban elimination
- Lower plasma edoxaban concentrations
- Potentially reduce anticoagulant efficacy
The guidelines specifically list P-glycoprotein inhibitors as reasons to reduce dose because they increase drug levels. Phenytoin does the opposite—it decreases drug levels. Using 30 mg in this context would create dangerously low edoxaban exposure, increasing thromboembolism risk.
Evidence Supporting Your Decision
The ENGAGE AF-TIMI 48 trial data 3 demonstrated that dose reduction decreased mean edoxaban exposure by 29-35% and anti-Factor Xa activity by 20-25%. While this was appropriate for patients meeting dose reduction criteria, applying this reduction to a patient on a P-glycoprotein inducer would compound the drug interaction effect, potentially resulting in subtherapeutic anticoagulation.
Recent real-world data 4 showed that low edoxaban concentrations (<12 ng/mL for 30 mg dose) were significantly associated with increased risk of ischemic stroke and systemic thromboembolism (adjusted HR 4.13,95% CI 1.08-15.82). Patients with higher creatinine clearance were particularly prone to low concentrations when receiving reduced doses.
Critical Pitfalls to Avoid
Do not inappropriately reduce the edoxaban dose. A 2019 study 5 found that the most frequent inappropriate use of edoxaban was dose adjustment (60.8% of inappropriate cases), particularly in patients with borderline body weight. The study identified body weight <60 kg as a factor associated with inappropriate dosing decisions (adjusted OR 0.310).
The 2024 ESC Guidelines explicitly warn 1: "A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria, to prevent underdosing and avoidable thromboembolic events."
Monitoring Considerations
While routine monitoring is not required, consider the following for this patient:
- Assess renal function: If creatinine clearance is 15-50 mL/min, this would be an independent indication for 30 mg, but you would need to weigh this against the phenytoin interaction
- Verify exact body weight: If truly ≤60 kg (not approximately), this creates a clinical dilemma requiring careful risk-benefit assessment
- Consider anti-Factor Xa monitoring: Given the drug interaction, measuring trough edoxaban levels could help confirm adequate anticoagulation (therapeutic range 12-43 ng/mL) 4
Your clinical instinct to maintain 60 mg is sound and aligns with guideline principles of avoiding underdosing that could lead to preventable thromboembolic events.